# Information Visualization Meets Biology: Models and Methods for Collaboration

#### Tamara Munzner

Department of Computer Science University of British Columbia

Keynote, VIZBI 2017 June 16 2017, Sydney Australia

www.cs.ubc.ca/~tmm/talks.html#vizbi17



### Visualization (vis) defined & motivated

**Computer-based visualization systems provide visual representations of datasets** designed to help people carry out tasks more effectively.

Visualization is suitable when there is a need to augment human capabilities rather than replace people with computational decision-making methods.

- human in the loop needs the details
  - -doesn't know exactly what questions to ask in advance
  - -longterm exploratory analysis
  - -presentation of known results
  - -stepping stone towards automation: refining, trustbuilding
- external representation: perception vs cognition
- intended task, measurable definitions of effectiveness

more at:

Visualization Analysis and Design, Chapter I. Munzner. AK Peters Visualization Series, CRC Press, 2014.



Visualization Analysis & Design

Tamara Munzner



# **A Nested Model**

### for Visualization Design and Validation

http://www.cs.ubc.ca/labs/imager/tr/2009/NestedModel

A Nested Model for Visualization Design and Validation. Munzner. IEEE Trans. Visualization and Computer Graphics (Proc. InfoVis 09), 15(6):921-928, 2009.

on	
raction	
oding/interaction idiom	
hm	

#### Tamara Munzner @tamaramunzner




### Vis analysis framework: Four levels, three questions

• domain situation

-who are the target users? what are their needs & concerns?


- abstraction
  - -translate from specifics of domain to vocabulary of vis
  - -what is shown? data abstraction
    - often don't just draw what you're given: transform to new form
  - -why is the user looking at it? task abstraction
- idiom
  - -how is it shown?
    - visual encoding idiom: how to draw
    - interaction idiom: how to manipulate
- algorithm
  - -efficient computation

Brehmer and Munzner. IEEETVCG 19(12):2376-2385, 2013 (Proc. InfoVis 2013).] more at: Visualization Analysis and Design, Ch 2/3/4. Munzner, CRC Press, 2014. 4



[A Nested Model of Visualization Design and Validation.

Munzner. IEEE TVCG 15(6):921-928, 2009 (Proc. InfoVis 2009). ]



[A Multi-Level Typology of Abstract Visualization Tasks

### Why is validation difficult?

• different ways to get it wrong at each level

Domain situation You misunderstood their needs

**Data/task abstraction**You're showing them the wrong thing

Wisual encoding/interaction idiom The way you show it doesn't work

Algorithm Your code is too slow

[A Nested Model of Visualization Design and Validation. Munzner. IEEE TVCG 15(6):921-928, 2009 (Proc. InfoVis 2009).]

### Validation solution: use methods from appropriate fields at each level

#### • avoid mismatches!

anthropology/ ethnography

design

computer science

cognitive psychology

anthropology/ ethnography

Domain situation Observe target users using existing tools	
Data/task abstraction	
Visual encoding/interaction idiom Justify design with respect to alternatives	
Algorithm Measure system time/memory Analyze computational complexity	tec wo
Analyze results qualitatively Measure human time with lab experiment ( <i>lab study</i> )	
Observe target users after deployment (field study)	
Measure adoption	

[A Nested Model of Visualization Design and Validation. Munzner. IEEE TVCG 15(6):921-928, 2009 (Proc. InfoVis 2009).]






#### hnique-driven ork

6

#### Angles of attack: My own research agenda




### Vis meets bio

- biology encompasses many rich application domain for vis collaboration
  - -challenging multi-level problems that won't be automated away any time soon
  - -complex tasks, complex datasets
  - -often existing infrastructure of computational workflows
    - many points where human-in-the-loop decision-making could bear fruit
- landscape of possible tools
  - -axis from eureka to speedup
    - sexy use case: eureka moment
      - enable what was impossible before: vis tools for new insights & discoveries
    - workhorse use case: workflow speedup
      - vis tools to accelerate what you're already doing
      - sometimes enables the previously infeasible

-axis from targeted to address specific pain points, to general purpose for broad use

### **Collaboration incentives: Bidirectional**

- what's in it for bio?
  - -bio win: access to more suitable tools, can do better/faster/cheaper science
  - -time spent could pay off with earlier access and/or more customized tools
- what's in it for vis?
  - -vis win: access to better understanding of your driving problems
    - crucial element in building effective tools to help
  - -opportunities to observe how you use them
    - if they're good enough, vis win: research success stories
  - -leads us to develop guidelines on how to build better tools in general
    - vis win: research progress in visualization
    - [The Computer Scientist as Toolsmith II, Fred Brooks, CACM 30(3):61-68 [996]



# Design Study Methodology

#### **Reflections from the Trenches and from the Stacks**

http://www.cs.ubc.ca/labs/imager/tr/2012/dsm/

Design Study Methodology: Reflections from the Trenches and from the Stacks. SedImair, Meyer, Munzner. IEEE Trans. Visualization and Computer Graphics 18(12): 2431-2440, 2012 (Proc. InfoVis 2012).

#### Michael SedImair



#### Miriah Meyer







#### Tamara Munzner @tamaramunzner




### Design Studies: Lessons learned after 21 of them





MostVis in-car networks



Car-X-Ray in-car networks



ProgSpy2010 in-car networks



RelEx in-car networks




Cardiogram in-car networks



Constellation linguistics



LibVis cultural heritage




Caidants multicast



**SessionViewer** web log analysis

and a		100	-	-			
-	- 100		5	in a second		Etc.	
	a series		1		34.	the.	
-	- deserve		.3	1	1	38.	
-						1	ł
2							
		-				1.0.00	

LiveRAC server hosting



**PowerSetViewer** data mining

commonality of representations cross-cuts domains!






QuestVis sustainability




**WiKeVis** in-car networks



AutobahnVis in-car networks



VisTra in-car networks



LastHistory music listening


### Methodology for problem-driven work


• definitions


• 9-stage framework

• 32 pitfalls & how to avoid them

comparison to related methodologies








dvance: jumping forward over stages	general
tart: insufficient knowledge of vis literature	learn
commitment: collaboration with wrong people	winnow
available (yet)	winnow
time available from potential collaborators	winnow
visualization: problem can be automated	winnow
expertise does not match domain problem	winnow
research: engineering vs. research project	winnow
change: existing tools are good enough	winnow

#### Design study methodology: definitions


- design studies: problem-driven work
  - -in collaboration with target users
    - real data, real tasks
    - intensive requirements analysis
  - -iterative refinement
    - rapid prototyping
    - deploy tools/systems to target users
  - -typical evaluation: field studies
    - case studies provide evidence of utility for target users
      - replicate known results quickly/easily: show workflow speedup
      - examples of new results found using tool


13

#### Design study methodology: definitions




ORITHM MATION SSIBLE
mputer











discover
design
implement
deploy

reflect write	
ANALYSIS	

• guidelines: confirm, refine, reject, propose







### Design study methodology: 32 pitfalls

• and how to avoid them

PF-1	premature advance: jumping forward over stages	general
PF-2	premature start: insufficient knowledge of vis literature	learn
PF-3	premature commitment: collaboration with wrong people	WINNOW
PF-4	no real data available (yet)	winnow
PF-5	insufficient time available from potential collaborators	winnow
PF-6	no need for visualization: problem can be automated	winnow
PF-7	researcher expertise does not match domain problem	winnow
PF-8	no need for research: engineering vs. research project	winnow
PF-9	no need for change: existing tools are good enough	winnow



### PREMATURE Collaboration Commitment

l'm a domain expert! Wanna collaborate?

(1)


N


COLLABORATOR





# METAPHOR Winnowing














#### initial conversation further meetings Talk with many, prototyping stay with few! full collaboration




### Design study methodology: 32 pitfalls

• and how to avoid them


PF-1	premature advance: jumping forward over stages	general
PF-2	premature start: insufficient knowledge of vis literature	learn
PF-3	premature commitment: collaboration with wrong people	winnow
PF-4	no real data available (yet)	winnow
PF-5	insufficient time available from potential collaborators	winnow
PF-6	no need for visualization: problem can be automated	winnow
PF-7	researcher expertise does not match domain problem	winnow
PF-8	no need for research: engineering vs. research project	winnow
PF-9	no need for change: existing tools are good enough	winnow

### considerations



### Design study methodology: 32 pitfalls

PF-10	no real/important/recurring task	winnow
PF-11	no rapport with collaborators	winnow
PF-12	not identifying front line analyst and gatekeeper before start	cast
PF-13	assuming every project will have the same role distribution	cast
PF-14	mistaking fellow tool builders for real end users	cast
PF-15	ignoring practices that currently work well	discover
PF-16	expecting just talking or fly on wall to work	discover
PF-17	experts focusing on visualization design vs. domain problem	discover
PF-18	learning their problems/language: too little / too much	discover
PF-19	abstraction: too little	design
PF-20	premature design commitment: consideration space too small	design





### Examples from the trenches

- premature collaboration
- fellow tool builders with inaccurate assumptions about user needs
- data unavailable early so didn't diagnose problems

PowerSet Viewer 2 years / 4 researchers

WikeVis 0.5 years / 2 researchers





### Design study methodology: 32 pitfalls

<b>PF-10</b>	no real/important/recurring task	winnow
<b>PF-1</b> 1	no rapport with collaborators	winnow
PF-12	not identifying front line analyst and gatekeeper before start	cast
PF-13	assuming every project will have the same role distribution	cast
PF-14	mistaking fellow tool builders for real end users	cast
PF-15	ignoring practices that currently work well	discover
PF-16	expecting just talking or fly on wall to work	discover
PF-17	experts focusing on visualization design vs. domain problem	discover
PF-18	learning their problems/language: too little / too much	discover
PF-19	abstraction: too little	design
PF-20	premature design commitment: consideration space too small	design





### **PREMATURE DESIGN** COMMITMENT

I want a tool with that cool technique | saw the other day!

(1)


COLLABORATOR






# Of course they need the **cool technique** I built last year!

# METAPHOR Design Space





# METAPHOR Design Space






#### small scope

#### Design study methodology: 32 pitfalls

• and how to avoid them


<b>PF-1</b>	premature advance: jumping forward over stages	general
PF-2	premature start: insufficient knowledge of vis literature	learn
PF-3	premature commitment: collaboration with wrong people	winnow
PF-4	no real data available (yet)	winnow
PF-5	insufficient time available from potential collaborators	winnow
PF-6	no need for visualization: problem can be automated	winnow
PF-7	researcher expertise does not match domain problem	winnow
PF-8	no need for research: engineering vs. research project	winnow
PF-9	no need for change: existing tools are good enough	winnow

# METAPHOR Design Space






# METAPHOR Design Space






#### broad scope


# Metaphor **Design Space**



# Metaphor **Design Space**




# Metaphor **Design Space**



# propose

## select

# METAPHOR Design Space




#### Design study methodology: 32 pitfalls

PF-10	no real/important/recurring task	winnow
<b>PF-11</b>	no rapport with collaborators	winnow
PF-12	not identifying front line analyst and gatekeeper before start	cast
PF-13	assuming every project will have the same role distribution	cast
PF-14	mistaking fellow tool builders for real end users	cast
PF-15	ignoring practices that currently work well	discover
PF-16	expecting just talking or fly on wall to work	discover
PF-17	experts focusing on visualization design vs. domain problem	discover
PF-18	learning their problems/language: too little / too much	discover
PF-19	abstraction: too little	design
PF-20	premature design commitment: consideration space too small	design



## **PREMATURE DESIGN** COMMITMENT


## **DOMAIN EXPERTS FOCUSED ON VIS DESIGN VS DOMAIN** PROBLEM



(OLLABORATOR

#### Design study methodology: 32 pitfalls

PF-21	mistaking technique-driven for problem-driven work	design
PF-22	nonrapid prototyping	implement
PF-23	usability: too little / too much	implement
PF-24	premature end: insufficient deploy time built into schedule	deploy
PF-25	usage study not case study: non-real task/data/user	deploy
PF-26	<i>liking</i> necessary but not sufficient for validation	deploy
PF-27	failing to improve guidelines: confirm, refine, reject, propose	reflect
PF-28	insufficient writing time built into schedule	write
PF-29	no technique contribution $\neq$ good design study	write
PF-30	too much domain background in paper	write
PF-31	story told chronologically vs. focus on final results	write
PF-32	premature end: win race vs. practice music for debut	write



Visualizing Sequence Variants in their Gene Context

http://www.cs.ubc.ca/labs/imager/tr/2012/VariantView/

Variant View: Visualizing Sequence Variants in their Gene Context. Ferstay, Nielsen, Munzner. IEEE TVCG 19(12): 2546-2555, 2013 (Proc. InfoVis 2013).

#### Joel Ferstay



#### Cydney Nielsen @cydneybn



#### Tamara Munzner @tamaramunzner



#### Variant View: Visualization Design Study

- first after DSM, tried following guidelines explicitly
- a specific real-world problem


-real users and real data,


- -collaboration is (often) fundamental
- design a visualization system -implications: requirements, multiple ideas
- validate the design

-at appropriate levels: case studies via deployment


- reflect about lessons learned
  - -transferable research: improve design guidelines for vis in general
    - confirm, refine, reject, propose

#### Sequence Variant Definition





## **Reference Genome DNA:** ATA TGA TCA ACA CTT ATA TGG TCA ATA CTT Harmful? Sample I Genome DNA: ATA TGA TGA ACA CCT Sample 2 Genome DNA:



#### Cancer Research

- collaboration with analysts at BC Genome Sciences Center -studying genetic basis of leukemia
- driving task

-discover new candidate genes with harmful variants

- two big questions
  - -what to show
    - data abstraction
    - challenge: enormous range of scales in the data
  - -how to show it
    - visual encoding idiom
    - challenge: information density and perceptual considerations

## Abstractions


#### domain

abstraction

idiom


algorithm

#### Data: Filtering to relevant biological levels and scales




/		


#### Filter out whole genome; keep genes



#### Filter out non-exon regions




#### Data abstraction: highly filtered scope of transcript coordinates






### Dominant paradigm: genome browsers

- strengths: flexible and powerful
  - -horizontal tracks: user data
  - -shared coordinate system: genome coordinates (bp)
- problems
  - tiny features of interest
     spread out across large
     extent
    - must zoom far in to inspect known feature, then zoom out and pan to locate next
    - high cognitive load for interaction
    - must already know where to look



#### representative example: Ensembl Chen et al, BMC Bioinforrmatics 2010.

#### Features of interest small even in variant-specific view





#### Exon regions small

#### Color coding difficult to see

Ensembl Variant Image Chen et al, BMC Bioinforrmatics 2010.



#### domain

abstraction

idiom

algorithm

	arch:									
Alternativ	ve Transc	ripts: g	ene-anon (tra	ns-anon)	]					A
Variants Mutation Typ Reference A Variant A.A.s	.A.s		× × × × × × × × × × × × × × × × × × ×							
Transcrip	ot	YP							- Y	
trans-anon										
Protein										
A.A. Chain										
Domains Regions								μ		
Active Sites Bindings Mod. Residu								Ι.		$ \cdot \cdot  $
Bindings								'		
Bindings Mod. Residu Variant D Patient ID	Oata Chr. Coord.		Var Base	dbSNP129	dbSNP135	dbSNP137	COSMIC	A.A. Chng.	Gene	
Bindings Mod. Residu Variant D Patient ID pid-anon	0ata Chr. Coord. 11288816	G	Var Base	dbSNP129	dbSNP135	dbSNP137	"13028,	G60V	gene-anon	I I I I
Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon	Chr. Coord. 11288816 11288816	G G	Var Base T T	dbSNP129		dbSNP137	"13028, "13012,	G60V D61Y	gene-anon gene-anon	trans-anon
Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon	Chr. Coord. 11288816 11288816 11288819	G G	Var Base T T T	dbSNP129	dbSNP135 rs121918	dbSNP137	"13028, "13012, 13014	G60V D61Y A72S	gene-anon gene-anon gene-anon	trans-anon trans-anon
Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon	Chr. Coord. 11288816 11288816 11288819 11288819 11288819	G G C	T T T T			dbSNP137	"13028, "13012, 13014 "13035,	G60V D61Y A72S A72V	gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon
Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon	Chr. Coord. 11288816 11288816 11288819 11288819 11288819 11288821	G G C G	T T T C		rs121918	dbSNP137	"13028, "13012, 13014 "13035, "13016,	G60V D61Y A72S A72V E76Q	gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon
Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon pid-anon	Chr. Coord. 11288816 11288816 11288819 11288819 11288821 11288821	G G C G A	T T T C G		rs121918	dbSNP137	"13028, "13012, 13014 "13035,	G60V D61Y A72S A72V E76Q E76G	gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon trans-anon
Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon	Pata Chr. Coord. 11288816 11288816 11288819 11288819 11288821 11288821 11288821	G G C G A G	T T T C G T		rs121918 rs121918	dbSNP137	"13028, "13012, 13014 "13035, "13016, "13017,	G60V D61Y A72S A72V E76Q E76G E76G	gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon trans-anon
Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon	Pata Chr. Coord. 11288816 11288816 11288819 11288819 11288821 11288821 11288821 11288821 11288821 11292688	G G C G A G T	T T T C G		rs121918 rs121918	dbSNP137	"13028, "13012, 13014 "13035, "13016, "13017, "13020,	G60V D61Y A72S A72V E76Q E76G E76D S502T	gene-anon gene-anon gene-anon gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon trans-anon trans-anon
Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon	Pata Chr. Coord. 11288816 11288816 11288819 11288819 11288821 11288821 11288821	G G C G A G	T T T C G T	• • • • • •	rs121918 rs121918	dbSNP137	"13028, "13012, 13014 "13035, "13016, "13017,	G60V D61Y A72S A72V E76Q E76G E76G	gene-anon gene-anon gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon trans-anon trans-anon

Sort B	By Gene:
Vipha	Cluster Score Variant Count
	DNMT3A (NM_022552)
	IDH2 (NM_002168)
	FLT3 (NM_004119)
	ANKRD36 (NM_001164315)
	ARID1B (NM_017519)
	STAG2 (NM_001042749)
	TNRC18 (NM_001080495)
	WT1 (NM_000378)
	ABCA13 (NM_152701)
	CEBPA (NM_004364)
	TET2 (NM_001127208)
	DNAH10 (NM_207437)
	GPSM1 (NM_015597)
	ASXL1 (NM_015338)
	DNAH1 (NM_015512)
	DNAH6 (NM_001370)
	FAT1 (NM_005245)
	MDN1 (NM_014611)
	PTPN11 (NM_002834)
	SYNE1 (NM_033071)
	ALMS1 (NM_015120)
	C10orf68 (NM_024688)
	CCDC88C (NM_001080414)
	DNAH11 (NM_003777)
	DNAH3 (NM_017539)
	DNAH9 (NM_001372)

Gene Sea	arch:				Submit				nior	matic
Alternativ Variants Mutation Typ Reference A Variant A.A.s Transcrip	De A.s S		ene-anon (tra	ns-anon)					8 0 0 0 0 0 5 5 5 T A L	A
trans-anon										
trans-anon Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu	le									
Protein A.A. Chain Domains Regions Active Sites Bindings										
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID	Data Chr. Coord.		Var Base	dbSNP129	dbSNP135 d	IbSNP137	COSMIC	A.A. Chng.	Gene	
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID	Data Chr. Coord. 11288816	G	Var Base T			IbSNP137	"13028,	G60V	gene-anon	I I I I
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon	Data Chr. Coord. 11288816 11288816	G G				bSNP137	"13028, "13012,	G60V D61Y	gene-anon gene-anon	I I I I I
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID pld-anon	Data Chr. Coord. 11288816	G G	T T T			IbSNP137	"13028,	G60V	gene-anon gene-anon	I I I I I
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon	Data Chr. Coord. 11288816 11288816	G G				IbSNP137	"13028, "13012,	G60V D61Y	gene-anon gene-anon gene-anon	
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon	Data Chr. Coord. 11288816 11288816 11288819	G G	T T T		rs121918	bSNP137	"13028, "13012, 13014	G60V D61Y A72S	gene-anon gene-anon gene-anon	trans-anon trans-anon
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon	Data Chr. Coord. 11288816 11288816 11288819 11288819	G G C	T T T T		rs121918	IbSNP137	"13028, "13012, 13014 "13035,	G60V D61Y A72S A72V	gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon pid-anon	Data Chr. Coord. 11288816 11288816 11288819 11288819 11288821	G G C G	T T T C		rs121918	IbSNP137	"13028, "13012, 13014 "13035, "13016,	G60V D61Y A72S A72V E76Q	gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon	Data Chr. Coord. 11288816 11288816 11288819 11288819 11288821 11288821	G G C G A	T T T C G		rs121918 rs121918	IbSNP137	"13028, "13012, 13014 "13035, "13016, "13017,	G60V D61Y A72S A72V E76Q E76G	gene-anon gene-anon gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon
Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon	Data Chr. Coord. 11288816 11288816 11288819 11288819 11288821 11288821 11288821 11288821	G G C G A G	T T T C G T		rs121918 rs121918	bSNP137	"13028, "13012, 13014 "13035, "13016, "13017,	G60V D61Y A72S A72V E76Q E76G E76D	gene-anon gene-anon gene-anon gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon trans-anon

#### -dense single gene view

	Cluster Score Variant Count	]
۵	DNMT3A (NM_022552)	
I	DH2 (NM_002168)	/
F	ELT3 (NM_004119)	1
ļ	NKRD36 (NM_001164315)	
A	ARID1B (NM_017519)	
\$	STAG2 (NM_001042749)	
1	NRC18 (NM_001080495)	
٧	VT1 (NM_000378)	
1	BCA13 (NM_152701)	
¢	CEBPA (NM_004364)	
1	ET2 (NM_001127208)	
۵	DNAH10 (NM_207437)	
0	3PSM1 (NM_015597)	
ļ	SXL1 (NM_015338)	
۵	DNAH1 (NM_015512)	
۵	DNAH6 (NM_001370)	
F	AT1 (NM_005245)	
٨	/IDN1 (NM_014611)	
F	PTPN11 (NM_002834)	
ŝ	SYNE1 (NM_033071)	
1	LMS1 (NM_015120)	
¢	C10orf68 (NM_024688)	
¢	CCDC88C (NM_001080414)	
۵	DNAH11 (NM_003777)	
۵	DNAH3 (NM_017539)	
C	DNAH9 (NM_001372)	


Gene Sea	arch:				Submit				Infor	matio	on-
Variants Mutation Typ Reference A Variant A.A.: Transcrip trans-anon Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu	Dt		ene-anon (tra	ns-anon)							Sort
Patient ID pid-anon pid-anon	Chr. Coord. 11288816 11288816		Var Base T T	dbSNP129	dbSNP135	dbSNP137	COSMIC "13028, "13012,	AA.Ch G60V D61Y	Noı	neec	l fo
pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon pid-anon	11288819 11288819 11288821 11288821 11288821 11288821 11292688 11292688	G G A G T T C	T C G T A G T		rs121918 rs121918 rs121918		13014 "13035, "13016, "13017, "13020, "13020, 13023	A72S A72V E76Q E76G E76D S502T S502A S502L	gene-anon gene-anon gene-anon gene-anon gene-anon	trans-anon trans-anon trans-anon trans-anon trans-anon trans-anon trans-anon	

#### -dense single gene view

+ 5	u Gono:	
	By Gene:	
ha	Cluster Score Variant	Count
	DNMT3A (NM_022552)	$\frown$
	IDH2 (NM_002168)	(C)
	FLT3 (NM_004119)	$\sim$
	ANKRD36 (NM_001164315)	
	ARID1B (NM_017519)	
	STAG2 (NM_001042749)	
	TNRC18 (NM_001080495)	
	WT1 (NM_000378)	
	ABCA13 (NM_152701)	
	CEBPA (NM_004364)	
	TET2 (NM_001127208)	_
	DNAH10 (NM_207437)	
	GPSM1 (NM_015597)	
	ASXL1 (NM_015338)	
	DNAH1 (NM_015512)	
	DNALIS (NM 001370)	

#### or pan and zoom


- ALMS1 (NM\_015120)
- C10orf68 (NM\_024688)
- CCDC88C (NM\_001080414)
- DNAH11 (NM\_003777)
- DNAH3 (NM\_017539)
- DNAH9 (NM\_001372)




## derived data guides human-in-the-loop analytics

2v	Gene		
l	Cluster Score Variant	Count	
r	DNMT3A (NM_022552)	6	
	DH2 (NM_002168)	(C	)
	FLT3 (NM_004119)	C	1
	ANKRD36 (NM_001164315)		
	ARID1B (NM_017519)		
	STAG2 (NM_001042749)		
1	INRC18 (NM_001080495)		
٧	WT1 (NM_000378)		
1	ABCA13 (NM_152701)		
¢	CEBPA (NM_004364)		
1	TET2 (NM_001127208)		
C	DNAH10 (NM_207437)		
¢	3PSM1 (NM_015597)		
1	ASXL1 (NM_015338)		
C	DNAH1 (NM_015512)		
۵	DNAH6 (NM_001370)		
F	FAT1 (NM_005245)		
N	MDN1 (NM_014611)		
F	PTPN11 (NM_002834)		
ŝ	SYNE1 (NM_033071)		
1	ALMS1 (NM_015120)		
(	C10orf68 (NM_024688)		
(	CCDC88C (NM_001080414		
۵	DNAH11 (NM_003777)		
0	DNAH3 (NM_017539)		
۵	DNAH9 (NM_001372)		

Variant View



Gene Sea	arch:				Submit						
Alternativ Variants Mutation Typ Reference A Variant A.A.s Transcrip trans-anon Protein A.A. Chain Domains Regions Active Sites Bindings Mod. Residu Variant D Patient ID	oe .A.s s ot 	C C C C C C C C C C C C C C C C C C C	v Q G D	dbSNP129	dbSNP135	dbSNP137	COSMIC	A.A. Chng.	SSS TAL I		Sor
pid-anon	11288816	G	T				"13028,	G60V	gene-anon	trans-anon	
pid-anon	11288816	G	T		5		"13012,	D61Y	_	_	
pid-anon	11288819	G	T		rs121918			A72S		nhai	$\sim$
pid-anon	11288819	С	T				*13035,	FIRE C	-er l	phe	d
pid-anon	11288821	G	C		1		"13016,		••••		
pid-anon	11288821	A	G		rs121918		"13017,	E76G			
pid-anon	11288821	G	Т					E76D		trans-anon	
pid-anon	11292688	Т	A		rs121918		"13020,	S502T		trans-anon	
pid-anon	11292688	Т	G				"13020,	S502A	gene-anon		
pid-anon	11292688	С	Т				13023	S502L	gene-anon	trans-anon	




DNAH11 (NM\_003777)

DNAH3 (NM\_017539)


DNAH9 (NM\_001372)

- show all attributes necessary for variant analysis
  - -match salience with importance for analysis task
- variant not just a thin line!
- emphasize with high salience


   collocated variants fan out at top
  - -grey variant vertical stroke intersects horizontal colored protein regions























#### Variant Type Stop Indel Deletion Insertion Splice Frameshift Nonsynonym Variant




#### Variant Type Stop Indel Deletion Insertion Splice Frameshift Nonsynonym Variant




#### Variant Type Stop Indel Deletion Insertion Splice Frameshift Nonsynonym Variant Transcript/Region Colours: Transcript AA Chain All Other Regions Non-Intersected Regions




## Known leukemia gene: Find fast with sorting metric high score




## Known leukemia gene: Fanout shows collocation of variants



## Known leukemia gene: Several functional protein regions affected




## New finding: Good candidate with high metric score







# New finding: Protein chemical class change evident




### Low scoring gene: in contrast




### Low scoring gene: No collocation of variants



## Low scoring gene: Mostly unaffected protein regions









- embedded within GSC for all stages
- winnow stage
  - -considered and ruled out many potential collaborators
- cast stage
  - -gatekeeper (PI)
  - -two front-line analysts (postdocs)





more at: Design Study Methodology: Reflections from the Trenches and from the Stacks. SedImair, Meyer, Munzner. IEEE TVCG 18(12): 2431-2440, 2012 (Proc. InfoVis 2012).



- main task abstraction
   –discover gene
- semi-structured interviews
  - -every week for 1 hr
- iterative refinement
  - -8 data sketches deployed
  - -rapid prototyping to show real data ASAP
  - -refine utility & usability








- two new analysts

   connected by
   enthusiastic gatekeeper
- new task abstractions

   compare patients
   debug pipeline
- transferrable with minimal changes



Variants Mutation Type Reference A.A.s Variant A.A.s	>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	0 0 >>>>	0 0 >>>>	0 >>>	0 0 >>>>
Transcript						
trans-anon						
Protein						
A.A. Chain Regions						
Comp. Biases Mod. Residue					l	

00000	 	_	 		-		_		-	-	-	_
												Т
												_
I T						I	I		I	I		

# Phase 4: Reflect and write




abstraction innovation

-data abstraction: highly filtered transcript coordinates (vs genome coordinates)


- guidelines
  - -specialize first, generalize later
    - good for domains with complex data
  - -high-level considerations
    - identifying scales of interest
    - what to visually encode directly vs what to support through interaction
    - when (and how) to eliminate navigation

A quick taste of other work!



### **Problem-driven: Genomics**

#### Aaron Barsky



### Jenn Gardy (Microbio)



(Harvard)

#### **Robert Kincaid** (Agilent)






Cerebral

#### Miriah Meyer





Hanspeter Pfister











### Problem-driven: Genomics, fisheries

### Joel Ferstay




### Cydney Nielsen (BC Cancer)



Variants ÷ + Mutation Type Reference A.A.s. Variant A.A.s. Öř Transcript trans-anon Protein A.A. Chain Signals Domains Regions Topo, Domai Transmem Active Sites NP Binding Metal Bind. Bindings Mod. Residue Carbohyd. Disuf.


#### **Variant View**



#### Maryam Booshehrian








#### Torsten Moeller (SFU)



### Problem-driven: Tech industry



#### Heidi Lam



### **Diane Tang** (Google)




#### SessionViewer: web log analysis

#### Peter McLachlan



#### Stephen North (AT&T Research)





#### LiveRAC: systems time-series









### Problem-driven: Journalism

#### Matt Brehmer



### Stephen Ingram



### Jonathan Stray





**Overview** 










### Technique-driven: Graph drawing



#### **TreeJuxtaposer**

#### James Slack



#### **Kristian Hildebrand**





#### Daniel Archambault



#### **David Auber** (Bordeaux)









**TopoLayout** SPF Grouse **GrouseFlocks** TugGraph

## Technique-driven: Dimensionality reduction

#### Stephen Ingram







 
 Normality
 Normality

 Addata (Jannae: Chemistrieth
 Sale formation

 Chemistrieth
 Sale formation


 Chemistrieth
 Sale formation

 Impart Rel per Mole (Sale) (Sale (Sale) (Sale (Sale) (Sale

Operators View

**DimStiller** 

Ministers.




**QSNE** 












### **Evaluation: Dimensionality reduction**

#### **Melanie Tory**






**Points vs landscapes for dimensionally** reduced data

Melanie Tory Michael Sedlmair (UVic)







#### **Taxonomy of cluster separation factors**



F

Ε




#### **Guidance on DR &** scatterplot choices

### **Curation & Presentation: Timelines**



### **TimeLineCurator**

### https://vimeo.com/123246662



#### **Timelines Revisited** timelinesrevisited.github.io/

#### Matt Brehmer



### Johanna Fulda (Sud. Zeitung)




#### Bongshin Lee (Microsoft)



Benjamin Bach Nathalie Henry-Riche (Microsoft)





# (Microsoft)


### Theoretical foundations

- Visual Encoding Pitfalls
  - Unjustified Visual Encoding
  - Hammer In Search Of Nail
  - 2D Good, 3D Better
  - Color Cacophony
  - Rainbows Just Like In The Sky

#### **Papers Process & Pitfalls**

- Strategy Pitfalls
- What I Did Over My Summer
- Least Publishable Unit
- Dense As Plutonium
- Bad Slice and Dice

### domain abstraction idiom algorithm



#### **Design Study Methodology**


### Michael Sedlmair




### Miriah Meyer



#### Matt Brehmer






#### **Abstract Tasks**



F

Ε



# Geometry Center 1990-1995





#### **Stuart Levy**

#### Mark Phillips







#### **Outside In**

#### **Delle Maxwell**



# Wrap-up

- models and methods for design and validation -collaboration incentives for vis and bio
- example biovis project

-Variant View

- methodological dream: user-centered design spreading from vis to biovis to bioinformatics
  - -task/requirements analysis for *all* tools, not just visual ones
  - -focus on both utility and usability


# More information


• this talk

<u>http://www.cs.ubc.ca/~tmm/talks.html#vizbi17</u>

papers, videos, software, talks, courses http://www.cs.ubc.ca/group/infovis http://www.cs.ubc.ca/~tmm

- theoretical foundations: book (+ free tutorial/course lecture slides) http://www.cs.ubc.ca/~tmm/vadbook
  - -20% promo code for book+ebook combo: HVN17
  - <u>http://www.crcpress.com/product/isbn/9781466508910</u>





#### (*a*)tamaramunzner



#### Visualization Analysis & Design

Tamara Munzner



Visualization Analysis and Design. Munzner. A K Peters Visualization Series, CRC Press, Visualization Series, 2014.